Reconnecting

The current page stays visible while onset.to reconnects in the background.

Connection error

onset.to could not restore the live connection within 5 seconds. Reload the page to recover.

Log in

Sources / Reddit

Reddit shroomstocks

Reddit

Investor discussion around psychedelic companies and market moves.

Most recent Latest added

Most recent Latest added

373 entries

Yesterday October 2, 2026

jamanetwork.com

jamanetwork.com · Undated

October 1, 2026

baltimoresun.com

baltimoresun.com · Undated

September 30, 2026

ir.compasspathways.com

ir.compasspathways.com · Undated

September 29, 2026

PharmAla reports a US$100 million ALA-002 licensing deal and New Zealand approval of MDMA-assisted PTSD therapy

mailchi.mp · Undated

Psilocybin MDMA Article Business +2

Psychedelic Medicine: The Next Frontier

youtube.com · Undated · Matthew Zorn

LSD Psilocybin Interview Clinical +2

September 26, 2026

Kapitalismus-Crash, Cash und Psychedelika: Investor Christian Angermayer über Exit, Gehirnchips und Bitcoin

welt.de · Sep 26, 2026 · Holger Zschäpitz, Nando Sommerfeldt, WELT

Podcast Business Industry Mainstream DE

September 24, 2026

muse.ai · Undated

Draulio Araújo on the path from ayahuasca research to controlled DMT trials for treatment-resistant depression

behavioralwire.com · Sep 24, 2026 · Editorial Desk

DMT Ayahuasca Article Clinical +2

A Single Supported Psilocybin Session Was Linked to Months of Reduced Cancer-Related Anxiety and Depression

mindbodygreen.com · Sep 24, 2026

Psilocybin Article Clinical Research Therapy

September 23, 2026

A Phase 1 trial tests psilocybin for borderline personality disorder while keeping dialectical behavior therapy in place

behavioralwire.com · Sep 23, 2026 · Editorial Desk

Psilocybin Article Clinical Research Safety

September 21, 2026

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

psychedelicalpha.com · Sep 21, 2026 · Josh Hardman

Ibogaine MDMA Podcast Industry +2

Cybin CEO Michael Halstead reports purchasing 100,000 common shares at a weighted average price of $13.4705

ir.helus.com · Sep 21, 2026 · Michael Halstead

Article Business Industry

How J&J's Spravato launch created the clinic infrastructure Compass needs for its potential COMP360 psychedelic rollout

biopharmadive.com · Sep 21, 2026 · Jacob Bell

Psilocybin Ketamine Article Business +2

September 18, 2026

Trade To Black Podcast: States Prepared For FDA Psychedelic Approval

youtube.com · Undated · Shadd Dales

Psilocybin Ibogaine Podcast Mainstream +3

bloomberg.com · Undated

Compass Pathways webcast scheduled for September 17, 2026, with registration and system test information

event.webcasts.com · Undated

Psilocybin Article Clinical Events Industry

Security check failure prevents access to the event content

event.webcasts.com · Undated

Article

September 17, 2026

Inside one woman’s psychedelic experiment to treat Lyme disease

washingtonpost.com · Sep 17, 2026 · Ariana Eunjung Cha

Psilocybin Article Clinical Industry

September 16, 2026

Pα+ Psychedelic Bulletin #231 covers Compass’s 52-week psilocybin follow-up, Xylo’s Phase I trial, ibogaine policy, and industry news

psychedelicalpha.com · Sep 16, 2026

Psilocybin Ibogaine Article Industry +2

September 15, 2026

FDA reclassifies NRx's generic ketamine amendment from Major to Minor, setting a November review goal after a vial-cap deficiency

behavioralwire.com · Sep 15, 2026 · Editorial Desk

Ketamine Article Industry Policy Safety

FDA hearing shifts the psychedelic approval debate toward who must deliver treatment and what training, oversight, and safety infrastructure are required

behavioralwire.com · Sep 15, 2026 · Behavioral Wire Staff

Psilocybin Article Clinical Policy Safety

It’s Time to Change the Tune in Treatment-Resistant Depression: Recognizing Cognitive Patterns, Brain Network Changes, and Patient Burden

changethetuneintrd.com · Undated

Article Clinical Research Therapy

FDA’s Psychedelics Public Hearing Draws Broad Support but No Questions from Federal Panel

psychedelicalpha.com · Sep 15, 2026 · Josh Hardman

Psilocybin Ketamine Article Policy +2

September 14, 2026

MycoMedica registers the first psilocybin trial for PMDD, testing repeated low doses without a mandated psychotherapy component

behavioralwire.com · Sep 14, 2026 · Editorial Desk

Psilocybin Article Clinical Industry Research

cdn-ceo-ca.s3.amazonaws.com

cdn-ceo-ca.s3.amazonaws.com · Undated